Loading...
OTCM
OCLG
Market cap73kUSD
Oct 06, Last price  
0.00USD
Jan 2017
-88.89%
Name

Oncologix Tech Inc

Chart & performance

D1W1MN
OTCM:OCLG chart
P/E
—
P/S
0.03
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
291.58%
Revenues
3m
-28.96%
157,83813,58028,670493,2601,061,0001,471,0002,163,0001,546,0001,174,000000000244,2463,677,0004,902,0004,012,0002,850,000
Net income
-2m
L+28.23%
-1,217,000-1,050,000-2,936,000-3,803,000-5,510,000-4,831,000-6,802,000-774,000-6,086,000-7,553,000-4,591,000-2,575,000-743,000-236,000-286,000-653,000-1,312,000-2,553,000-1,849,000-2,371,000
CFO
-24k
L
-868,811-711,344-1,435,162-1,117,928-1,739,834-1,665,935-440,288-558,504-555,788-3,080,529-1,297,308-130,816-225,349-178,538-119,381147,097-629,942-356,544344,918-24,204

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Oncologix Tech, Inc. is a biopharmaceutical company whose main products include DNAGO and genomego which provides clinical genetic testing on all 20,000+ genes encompassing over 7,000 rare genetic diseases. It also previously operated in personal home care services and the manufacturing and distribution of medical technologies. The company was formerly known as BestNet Communications Corp. and changed its name to Oncologix Tech, Inc. in January 2007.

Key people

Michael A. Kramarz
Chairman of the Board, Chief Executive Officer, Chief Financial Officer · since 2016
Roy Wayne Erwin
President · since 2016
Vickie G. Hart
President of Amian Angels, Inc. · since 2016
Harold Halman
Chief Operating Officer, Director · since 2016
URL
http://www.oclghealth.com
IPO date
Feb 11, 1987
Employees
191
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2022‑082021‑082020‑082019‑082017‑08
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT